Incidence of Hospitalization for Heart Failure Relative to Major Atherosclerotic Events in Type 2 Diabetes: A Meta-analysis of Cardiovascular Outcomes Trials - PubMed (original) (raw)
Meta-Analysis
. 2020 Oct;43(10):2614-2623.
doi: 10.2337/dc20-0654.
Affiliations
- PMID: 32958618
- DOI: 10.2337/dc20-0654
Meta-Analysis
Incidence of Hospitalization for Heart Failure Relative to Major Atherosclerotic Events in Type 2 Diabetes: A Meta-analysis of Cardiovascular Outcomes Trials
Julian W Sacre et al. Diabetes Care. 2020 Oct.
Abstract
Background: Emerging evidence points to heart failure as being a common first presentation of cardiovascular (CV) disease in type 2 diabetes.
Purpose: The purpose of this study was to determine whether hospitalization for heart failure (HHF) occurs more or less frequently than major adverse CV events (MACE) in people with type 2 diabetes.
Data sources: Placebo arms of CV outcomes trials in type 2 diabetes were included.
Study selection: Sixteen CV outcomes trials were selected, including five dipeptidyl peptidase 4 inhibitor trials, seven glucagon-like peptide 1 receptor agonist trials, and four sodium-glucose cotransporter 2 inhibitor trials.
Data extraction: We extracted incidence rates of HHF, myocardial infarction (MI), stroke, and the composite outcomes of CV death or HHF and MACE (CV death, nonfatal MI, or nonfatal stroke).
Data synthesis: In two trials enriched with people with chronic kidney disease, HHF was more common than both MI and stroke. Among the remaining 14 trials, HHF was less frequent than MI in 13 (93%), with this difference being significant in 8 (57%); however, HHF surpassed stroke in all but 1 study (93%; significant in 7 studies [50%]). Heterogeneity among trials was moderate/high (I 2 >50%) and partly explained by HHF/MI correlating with age and previous MI history (P < 0.05). In seven trials that reported events stratified by presence/absence of preexisting CV disease, ratios of HHF/MI and HHF/stroke were similar between groups.
Limitations: Enrichment of trial populations with those at high risk of CV events limits generalizability.
Conclusions: Although less frequent than MI, HHF is a common event in type 2 diabetes, both in those with and those without prior CV disease.
© 2020 by the American Diabetes Association.
Similar articles
- Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.
McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S, Pratley R, Greenberg M, Wang S, Huyck S, Gantz I, Terra SG, Masiukiewicz U, Cannon CP. McGuire DK, et al. JAMA Cardiol. 2021 Feb 1;6(2):148-158. doi: 10.1001/jamacardio.2020.4511. JAMA Cardiol. 2021. PMID: 33031522 Free PMC article. - Navigating the "MACE" in Cardiovascular Outcomes Trials and decoding the relevance of Atherosclerotic Cardiovascular Disease benefits versus Heart Failure benefits.
Hupfeld C, Mudaliar S. Hupfeld C, et al. Diabetes Obes Metab. 2019 Aug;21(8):1780-1789. doi: 10.1111/dom.13740. Epub 2019 Apr 29. Diabetes Obes Metab. 2019. PMID: 30957945 Review. - SAVOR-TIMI to SUSTAIN-6: a critical comparison of cardiovascular outcome trials of antidiabetic drugs.
Singh AK, Singh R. Singh AK, et al. Expert Rev Clin Pharmacol. 2017 Apr;10(4):429-442. doi: 10.1080/17512433.2017.1287562. Epub 2017 Feb 6. Expert Rev Clin Pharmacol. 2017. PMID: 28121469 Review.
Cited by
- Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial.
Sharma A, Razaghizad A, Joury A, Levin A, Bajaj HS, Mancini GBJ, Wong NC, Slee A, Ang FG, Rapattoni W, Neuen BL, Arnott C, Perkovic V, Mahaffey KW. Sharma A, et al. J Am Heart Assoc. 2024 Feb 6;13(3):e031586. doi: 10.1161/JAHA.123.031586. Epub 2024 Jan 19. J Am Heart Assoc. 2024. PMID: 38240199 Free PMC article. - Gaseous signal molecule SO2 regulates autophagy through PI3K/AKT pathway inhibits cardiomyocyte apoptosis and improves myocardial fibrosis in rats with type II diabetes.
Zhao J, Wu Q, Yang T, Nie L, Liu S, Zhou J, Chen J, Jiang Z, Xiao T, Yang J, Chu C. Zhao J, et al. Korean J Physiol Pharmacol. 2022 Nov 1;26(6):541-556. doi: 10.4196/kjpp.2022.26.6.541. Korean J Physiol Pharmacol. 2022. PMID: 36302628 Free PMC article. - Association of the KDIGO Risk Classification with the Prevalence of Heart Failure in Patients with Type 2 Diabetes.
Gimeno-Orna JA, Rodríguez-Padial L, Anguita-Sánchez M, Barrios V, Muñiz J, Pérez A. Gimeno-Orna JA, et al. J Clin Med. 2021 Oct 9;10(20):4634. doi: 10.3390/jcm10204634. J Clin Med. 2021. PMID: 34682756 Free PMC article. - Aldose Reductase: An Emerging Target for Development of Interventions for Diabetic Cardiovascular Complications.
Jannapureddy S, Sharma M, Yepuri G, Schmidt AM, Ramasamy R. Jannapureddy S, et al. Front Endocrinol (Lausanne). 2021 Mar 11;12:636267. doi: 10.3389/fendo.2021.636267. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33776930 Free PMC article. Review. - Sodium-glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes.
Giugliano D, Longo M, Scappaticcio L, Caruso P, Esposito K. Giugliano D, et al. Cardiovasc Diabetol. 2021 Jan 11;20(1):17. doi: 10.1186/s12933-021-01213-w. Cardiovasc Diabetol. 2021. PMID: 33430860 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical